1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Drugs In Development, 2022, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 26, 116, 74, 4, 19 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 4 and 9 molecules, respectively.
Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Peritoneal Cancer - Overview
- Peritoneal Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Peritoneal Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Peritoneal Cancer - Companies Involved in Therapeutics Development
- Peritoneal Cancer - Drug Profiles
- Peritoneal Cancer - Dormant Projects
- Peritoneal Cancer - Discontinued Products
- Peritoneal Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Peritoneal Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Peritoneal Cancer - Dormant Projects, 2022
- Peritoneal Cancer - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Peritoneal Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- AbbVie Inc
- Acrivon Therapeutics Inc
- ADC Therapeutics SA
- Advenchen Laboratories LLC
- AIM ImmunoTech Inc
- AiVita Biomedical Inc
- Akeso Inc
- Aldeyra Therapeutics Inc
- Alkermes Plc
- ALX Oncology Holdings Inc
- Amgen Inc
- Anixa Biosciences Inc
- Apexigen Inc
- APIM Therapeutics AS
- Apollomics Inc
- Aprea Therapeutics Inc
- Aravive Inc
- Arch Oncology Inc
- Artios Pharma Ltd
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Astellas Pharma Inc
- Astex Pharmaceuticals Inc
- AstraZeneca Plc
- Aurigene Discovery Technologies Ltd
- Basilea Pharmaceutica Ltd
- Bayer AG
- BeiGene Ltd
- Bio-Path Holdings Inc
- Bio-Thera Solutions Ltd
- BioAtla Inc
- BioIntegrator
- BioInvent International AB
- BioNTech SE
- Bristol-Myers Squibb Co
- Calithera Biosciences Inc
- Celldex Therapeutics Inc
- Celsion Corp
- CerRx Inc
- Clover Biopharmaceuticals Ltd
- Clovis Oncology Inc
- Coherent Biopharma
- Compugen Ltd
- Context Therapeutics Inc
- Corcept Therapeutics Inc
- Cotinga Pharmaceuticals Inc
- Cristal Therapeutics BV
- CSPC Pharmaceutical Group Ltd
- CytomX Therapeutics Inc
- Daiichi Sankyo Co Ltd
- EirGenix Inc
- Eisai Co Ltd
- Eli Lilly and Co
- Ellipses Pharma Ltd
- Elucida Oncology Inc
- ENB Therapeutics LLC
- Enlivex Therapeutics Ltd
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- FUJIFILM Toyama Chemical Co Ltd
- Genelux Corp
- Genentech USA Inc
- Genmab AS
- Gilead Sciences Inc
- Gradalis Inc
- Greenfire Bio LLC
- GSK plc
- Harpoon Therapeutics Inc
- Hutchison MediPharma Ltd
- I-Mab
- ImmunityBio Inc
- Immunocore Limited
- ImmunoGen Inc
- Immunotech Biopharm Ltd
- Immutep Ltd
- IMPACT Therapeutics Inc
- Imugene Ltd
- IMV Inc
- Incyte Corp
- Infinity Pharmaceuticals Inc
- Innovent Biologics Inc
- Inspirna Inc
- Instil Bio Inc
- InxMed (Beijing) Co Ltd
- Ionic Pharmaceuticals LLC
- Ipsen SA
- Jiangsu Hengrui Medicine Co Ltd
- Jina Pharmaceuticals Inc
- Johnson & Johnson
- Karyopharm Therapeutics Inc
- Kidswell Bio Corp
- Kupffer Biotherapeutics Inc
- Kyowa Kirin Co Ltd
- Laekna Therapeutics Shanghai Co Ltd
- Leap Therapeutics Inc
- Lee's Pharmaceutical Holdings Ltd
- Lipac Oncology LLC
- Lokon Pharma AB
- MabVax Therapeutics Holdings Inc
- Merck & Co Inc
- Merck KGaA
- Mereo Biopharma Group Plc
- Mersana Therapeutics Inc
- Morvus Technology Ltd
- MUCPharm Pty Ltd
- Mycenax Biotech Inc
- Northlake International LLC
- Northwest Biotherapeutics Inc
- Novartis AG
- NuCana Plc
- Nurix Therapeutics Inc
- Nuvation Bio Inc
- OBI Pharma Inc
- Oncoinvent AS
- OncoQuest Inc
- Oncovir Inc
- OncXerna Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Onxeo SA
- Orano Med LLC
- Pfizer Inc
- Pharma Mar SA
- PharmAbcine Inc
- Pharmicell Co Ltd
- Pharos iBio Co Ltd
- Pionyr Immunotherapeutics Inc
- Plexxikon Inc
- Precigen Inc
- Prestige BioPharma Ltd
- PsiOxus Therapeutics Ltd
- PTC Therapeutics Inc
- R-Pharm US LLC
- Recordati SpA
- Regeneron Pharmaceuticals Inc
- RemeGen Co Ltd
- Rhizen Pharmaceuticals SA
- Rigel Pharmaceuticals Inc
- Samyang Biopharmaceuticals Corp
- Sanofi
- Scancell Holdings Plc
- Seagen Inc
- SELLAS Life Sciences Group Inc
- Senhwa Biosciences Inc
- Shanghai De Novo Pharmatech Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shattuck Labs Inc
- Shenzhen Chipscreen Biosciences Co Ltd
- Sierra Oncology Inc
- Soricimed Biopharma Inc
- Sorrento Therapeutics Inc
- STADA Pharmaceuticals (Asia) Ltd
- Sumitomo Pharma Co Ltd
- Sutro Biopharma Inc
- Synermore Biologics Co Ltd
- SynOx Therapeutics Ltd
- Targovax ASA
- TILT Biotherapeutics Ltd
- Toray Industries Inc
- Transgene SA
- Ultimovacs AS
- Vascular Biogenics Ltd
- Verastem Inc
- Viatris Inc
- Vigeo Therapeutics Inc
- Vivesto AB
- Vyriad Inc
- Xynomic Pharmaceuticals Holdings Inc
- Y-mAbs Therapeutics Inc
- Zenith Epigenetics Ltd
- Zentalis Pharmaceuticals Inc
